In this issue of Blood, Wang et al compare the minimal residual disease (MRD) rate and outcome of patients with CLL treated with continuous ibrutinib plus 6 cycles of rituximab (IR) with that of those treated with FCR (fludarabine, cyclophosphamide and rituximab).(1) This study provides comparative data on the use of MRD in the management of CLL and emphasizes several pressing issues.
机构:
Autonomous Univ Madrid, Dept Neurol, Hosp Univ La Paz, Stroke Unit, Madrid 28046, SpainAutonomous Univ Madrid, Dept Neurol, Hosp Univ La Paz, Stroke Unit, Madrid 28046, Spain
Fuentes, Blanca
Diez-Tejedor, Exuperio
论文数: 0引用数: 0
h-index: 0
机构:
Autonomous Univ Madrid, Dept Neurol, Hosp Univ La Paz, Stroke Unit, Madrid 28046, SpainAutonomous Univ Madrid, Dept Neurol, Hosp Univ La Paz, Stroke Unit, Madrid 28046, Spain